11
Table 2. Selected Genetic Alterations Linked to FDA
Approvals as of June 2021
a
Genetic Alterations Tumor type Targeted Therapeutics
FDA-approved treatments for specific genetic alterations in specific tumor types
ALK fusions NSCLC Crizotinib, Ceritinib, Alectinib
Brigatinib, Lorlatinib
BRAF V600E
Melanoma
Dabrafenib, Vemurafenib
Dabrafenib + Trametinib,
Encorafenib + Binimetinib,
Vemurafenib + Cobimetinib,
Trametinib
Anaplastic thyroid cancer Dabrafenib + Trametinib
NSCLC Dabrafenib + Trametinib
Colorectal cancer Encorafenib + Cetuximab
BRAF V600K
Melanoma
Dabrafenib + Trametinib,
Encorafenib + Binimetinib,
Vemurafenib + Cobimetinib,
Trametinib
Deleterious or
a
suspected deleterious
germline or somatic
mutations in BRCA1
and/or BRCA2
Ovarian cancer, fallopian
tube cancer, peritoneal
cancer
Olaparib
a
, Rucaparib,
Niraparib
a
Prostate cancer
Olaparib
a
, Rucaparib
a
Deleterious or
suspected deleterious
germline mutations in
BRCA1 and/or BRCA2
Ovarian cancer, pancreatic
adenocarcinoma
Olaparib
HER2-negative breast
cancer
Olaparib, Talazoparib
Deleterious or
suspected deleterious
germline or somatic
mutations in ATM,
BARD1, BRIP1,
CDK12, CHEK1,
CHEK2, FANCL,
PALB2, RAD51B,
RAD51C, RAD51D,
RAD54L
Prostate cancer Olaparib
